Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2008 Sep;51(3):418-20. doi: 10.1002/pbc.21597.

Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome.

Author information

1
Department of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Minnesota, MMC 484, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USA. smith719@umn.edu

Abstract

Cutaneovisceral angiomatosis with thrombocytopenia (CAT) syndrome is a rare vascular disorder of the skin and gastrointestinal tract for which there is no standard treatment. We present a case in which a child with CAT syndrome was treated with bevacizumab, a vascular endothelial growth factor inhibitor, and subsequently developed asymptomatic metaphyseal bone lesions. Though not previously described as a side effect, we hypothesize that the use of bevacizumab in a child with active epiphyseal growth plates caused these radiographic lesions. Because of the potential for altered bone growth and metabolism, children receiving VEGF inhibitors should be monitored closely for bony toxicity.

PMID:
18493993
DOI:
10.1002/pbc.21597
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center